Graphical abstract. Credit: Journal of Clinical Investigation (2025). Doi: 10.1172/jCI179703
Northwestern medicine scientists have uncovered a key pathway controlling tumor growth in b-cael lymphomas, according to a study Published in the Journal of Clinical Investigation,
B-cael lymphoma, a type of cancer that starts in white blood cells called lymphocytes, accounts for 85 percent of non-hodgkin lymphoma diagnoses in the us each year.
Many subtypes of b-cael lymphomas are thought to be impacted by an imbalance beetween polycomb repressive complexes (PRC1/prc2) and the pr-dub commission Act Cancer Development has Remained Unclear.
“Some scientists belief that Bap1, The Enzymatic Subunit Within The Pr-Dub Complex, is a tumor suppressor because loss of bap1 was observed in some species,” Sistant Professor of Biochemistry and Molecular Genetics , Who was Senior Author of the Study.
“Buts others believe that Bap1 Functions as an oncode, beCause if you inhibit bap1 activity or genetically deplete of bap1 in a bap1-expressing tumor, the cells ALSO Die. her bap1 functions as a tumor suppressor Or Oncodene, and how it functions in a tumor context-dependent manner. “
In the current study, Investigators Analyzed Multiple Cultured Human Cancer Cell Lines with Bap1 and Compared Them to Cell Lines that Had Bap1 Inhibited. Through rna sequencing, they found that Bap1 Increased The Expression of Several MHC-II Zanees, which are known to play a critical role in the body’s immmune responses.
Next, scientists focused on b-cael lymphoma, which express high levels of functional mhc-II molecules. They found depletion of the bap1 gene in b-cael lymphoma cells reduced the immune cell infiltration and accelerated tumor growls.
Finally, Investigators inhibited polycomb repressive Complex 1 (PRC1), which work to antagonize bap1 activity, and found that it restored mhc-II ExPRESSION IN BAP1-EFCINENGENGEN IN BAP1-EFCINENGENG
“Bap1 and PrC1 Form a Balance,” said wang, who is also a member of the robert h. Lurie comprehensive cancer center of northwestern university. “These two enzymes control the proportionation levels of mhc-ii molecule. In a tumor, if you lose bap1, you lose that balance. Biting the antagonist, prc1 . “
TAKEN TOGETHER, The Findings May Prove Useful in Improving Immunotherapies for B-Cell Lymphomas, Wang Said. His laboratory is now working to develop effective prc1 inhibitors in hopes of improving current immunotherapies for b-cael lymphomas.
“We want to improve the compound in order to rescue MSC-II Expression and REESTABLISH The Tumor Microenvironment in Animal Models,” Wang said.
More information:
Te zhang et al, an epigenetic pathway regulates MHC-II Expression and Function in B Cell Lymphoma Models, Journal of Clinical Investigation (2025). Doi: 10.1172/jCI179703
Citation: Uncovering The Molecular Drivers of B-Cell Lymphoma Tumor Growth (2025, February 3) Retrieved 3 February 2025 from
This document is Subject to copyright. Apart from any Fair Dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
(Tagstotranslate) Medicine Research News (T) Medicine Research (T) Health Research News (T) Health Research (T) Health Science (T) Medicine Science